Ben-David Uri
Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Biochim Biophys Acta. 2015 Apr;1849(4):427-35. doi: 10.1016/j.bbagrm.2014.08.005. Epub 2014 Aug 15.
Cancer cells and stem cells share many traits, including a tendency towards genomic instability. Human cancers exhibit tumor-specific genomic aberrations, which often affect their malignancy and drug response. During their culture propagation, human pluripotent stem cells (hPSCs) also acquire characteristic genomic aberrations, which may have significant impact on their molecular and cellular phenotypes. These aberrations vary in size from single nucleotide alterations to copy number alterations to whole chromosome gains. A prominent challenge in both cancer and stem cell research is to identify "driver aberrations" that confer a selection advantage, and "driver genes" that underlie the recurrence of these aberrations. Following principles that are already well-established in cancer research, candidate driver genes have also been suggested in hPSCs. Experimental validation of the functional role of such candidates can uncover whether these are bona fide driver genes. The identification of driver genes may bring us closer to a mechanistic understanding of the genomic instability of stem cells. Guided by terminologies and methodologies commonly applied in cancer research, such understanding may have important ramifications for both stem cell and cancer biology. This article is part of a Special Issue entitled: Stress as a fundamental theme in cell plasticity.
癌细胞和干细胞具有许多共同特征,包括基因组不稳定的倾向。人类癌症表现出肿瘤特异性的基因组畸变,这常常影响其恶性程度和药物反应。在其培养增殖过程中,人类多能干细胞(hPSC)也会获得特征性的基因组畸变,这可能对其分子和细胞表型产生重大影响。这些畸变的大小各不相同,从单核苷酸改变到拷贝数改变,再到整条染色体的增加。癌症和干细胞研究中的一个突出挑战是识别赋予选择优势的“驱动畸变”以及这些畸变复发背后的“驱动基因”。遵循癌症研究中已确立的原则,hPSC中也已提出了候选驱动基因。对这些候选基因功能作用的实验验证可以揭示它们是否是真正的驱动基因。驱动基因的识别可能使我们更深入地了解干细胞基因组不稳定的机制。在癌症研究中常用的术语和方法的指导下,这种理解可能对干细胞生物学和癌症生物学都产生重要影响。本文是名为:应激作为细胞可塑性的基本主题的特刊的一部分。